Singapore markets closed

Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
1.160-0.020 (-1.69%)
At close: 03:36PM HKT
Currency in HKD

Valuation measures4

Market cap (intra-day) 1.77B
Enterprise value 732.18M
Trailing P/E 5.13
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.45
Price/book (mrq)0.58
Enterprise value/revenue 0.63
Enterprise value/EBITDA 1.45

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3-4.84%
S&P500 52-week change 326.94%
52-week high 31.350
52-week low 30.980
50-day moving average 31.203
200-day moving average 31.135

Share statistics

Avg vol (3-month) 3240.46k
Avg vol (10-day) 3142.7k
Shares outstanding 51.5B
Implied shares outstanding 61.55B
Float 8599.66M
% held by insiders 160.03%
% held by institutions 111.71%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.08
Forward annual dividend yield 46.56%
Trailing annual dividend rate 30.07
Trailing annual dividend yield 36.19%
5-year average dividend yield 45.08
Payout ratio 436.85%
Dividend date 3N/A
Ex-dividend date 428 May 2024
Last split factor 22:1
Last split date 306 Aug 2018

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 28.32%
Operating margin (ttm)16.93%

Management effectiveness

Return on assets (ttm)4.73%
Return on equity (ttm)11.71%

Income statement

Revenue (ttm)1.15B
Revenue per share (ttm)0.77
Quarterly revenue growth (yoy)-23.40%
Gross profit (ttm)N/A
EBITDA 354.43M
Net income avi to common (ttm)326M
Diluted EPS (ttm)0.230
Quarterly earnings growth (yoy)-62.40%

Balance sheet

Total cash (mrq)1.17B
Total cash per share (mrq)0.78
Total debt (mrq)120.53M
Total debt/equity (mrq)4.22%
Current ratio (mrq)2.57
Book value per share (mrq)1.90

Cash flow statement

Operating cash flow (ttm)338.4M
Levered free cash flow (ttm)-217.18M